Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modakafusp alfa in relapsed refractory multiple myeloma
NCT03215030Phase 2Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Oct 2017
- Primary completion
- Jul 2024
- Modality
- Antibody Fragments, Immunomodulatory ADCs, Cytokines & Interferons
- Countries
- 16
01
Overview
Phase 2, randomised, open-label trial of modakafusp alfa in multiple myeloma (MM) (12 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Treatment Emergent Adverse Events at 54.3 months, Dose-limiting Toxicities at Cycle 1 and 3 more. Started Oct 2017; status: terminated.
02
Drugs
modakafusp alfa
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03215030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03215030.